Ehteram Khademi Siahestalkhi

Dr. Ehteram Khademi Siahestalkhi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in Medical Oncology
Verified
Journal Article
Open access
PDF file
ESEhteram Khademi Siahestalkhi
Ehteram Khademi Siahestalkhi
ADAydın Demiray
Aydın Demiray
AYArzu Yaren
Arzu Yaren
ADAtike Gökçen Demiray
Atike Gökçen Demiray
STSeçil Tan
Seçil Tan
HAHakan AKCA¹˒³
Hakan AKCA¹˒³
Epithelial ovarian cancer (EOC) is the second leading cause of death among women with gynecological cancers, particularly in high-income countries. Despite significant advancements in molecular oncology and an initially positive response to primary chemotherapy, the development of drug resistance remains a major challenge in the effective management of EOC. Consequently, there is an urgent need for innovative biological markers that can enable early diagnosis and provide more accurate predictions of recurrence risk in ovarian cancer patients. This study investigated the expression profiles of seven specific long noncoding RNAs (lncRNAs)—SNHG7, TUG1, XIST1, PRLB, TLR8-AS1, ZFAS1, and PVT1—associated with epithelial ovarian cancer and their relationship with drug resistance. To achieve this, drug-resistant subtypes of aggressive EOC cell lines, including carboplatin/paclitaxel-resistant OVCAR3 and SKOV3 lines, were developed. The expression profiles of the selected lncRNAs were quantitatively analyzed using RT-qPCR across various ovarian cancer cell lines and in serum samples from 25 patients before chemotherapy, six months after treatment, and 23 healthy controls. The findings revealed that the target lncRNAs were significantly upregulated under drug-resistant conditions and in post-chemotherapy serum samples, suggesting their involvement in a complex regulatory network. These results highlight the critical roles of lncRNAs in the progression and treatment response of EOC, positioning them as potential therapeutic targets and biomarkers for early diagnosis and treatment stratification. Identifying reliable lncRNA biomarkers could enable the early detection of patients at risk for developing drug resistance, thereby facilitating personalized treatment strategies to improve patient outcomes and survival rates.

1 June 2024 in Iranian Journal of Blood and Cancer
Verified
Journal Article
Open access
PDF file
MOMeral Merve Oğuz
Meral Merve Oğuz
ESEhteram Khademi Siahestalkhi
Ehteram Khademi Siahestalkhi
AYArzu Yaren
Arzu Yaren
ADAydin Demiray
Aydin Demiray
ADAtike Gökçen Demiray
Atike Gökçen Demiray
Background: Colorectal cancer (CRC), a common and aggressive gastrointestinal cancer, presents significant challenges in diagnosis and prognosis prediction despite available detection and treatment options. Many studies emphasized the crucial link between abnormal microRNA regulation and their potential role in cancer development and progression. These miRNAs are recognized as important non-invasive biomarkers ...